DOCSLIB.ORG

Guanethidine Monosulfate (USAN, Rinnm) Had Little Effect in Either Patient

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Guanethidine Monosulfate (USAN, Rinnm) Had Little Effect in Either Patient 1300 Cardiovascular Drugs Pharmacopoeias. In Jpn and US. Uses and Administration dine, but authorities have differed as to whether the drug should USP 31 (Guanabenz Acetate). A white or almost white powder Guanadrel is an antihypertensive with actions and uses similar to be stopped before elective surgery. Former US licensed product with not more than a slight odour. Sparingly soluble in water and those of guanethidine (below). After oral administration, gua- information recommended stopping up to 2 or 3 weeks before- in 0.1N hydrochloric acid; soluble in alcohol and in propylene nadrel acts within 2 hours with the maximum effect after 4 to 6 hand. In patients undergoing emergency procedures or where glycol. A 0.7% solution in water has a pH of 5.5 to 7.0. Store in hours. The hypotensive effect is reported to last for 4 to 14 hours treatment has not been interrupted large doses of atropine should airtight containers. Protect from light. following a single dose. It has been given orally as the sulfate in be given before induction of anaesthesia. the management of hypertension, although it has largely been su- Patients undergoing treatment with eye drops containing Adverse Effects and Precautions perseded by other drugs less likely to cause orthostatic hypoten- As for Clonidine Hydrochloride, p.1247. guanethidine should be examined regularly for signs of conjunc- sion. tival damage. Overdosage. Overdosage with guanabenz has been reported.1 Preparations The main symptoms were lethargy, drowsiness, bradycardia, and Interactions hypotension. A 45-year-old woman who had taken 200 to USP 31: Guanadrel Sulfate Tablets. Patients taking guanethidine may show increased sensitivity to 240 mg of guanabenz with alcohol recovered after gastric lavage the action of adrenaline, amfetamine, and other sympathomimet- and intravenous fluids; a 3-year-old child who had taken 12 mg ics, resulting in exaggerated pressor effects. The hypotensive ef- fects may also be antagonised by tricyclic antidepressants, of guanabenz responded to atropine and dopamine. Naloxone Guanethidine Monosulfate (USAN, rINNM) had little effect in either patient. MAOIs, and phenothiazine derivatives and related antipsychot- Guanéthidine, monosulfate de; Guanethidine Monosulphate ics (although phenothiazines may also exacerbate orthostatic hy- 1. Hall AH, et al. Guanabenz overdose. Ann Intern Med 1985; 102: (BANM); Guanethidini Monosufas; Guanethidini monosulfas; potension, which may be more relevant clinically). In the UK 787–8. Guanethidini Sulfas; Guanethidin-monosulfát; Guanetidiinimono- licensed product information suggests that MAOIs should be Interactions sulfaatti; Guanetidinmonosulfat; Guanetidin-monoszulfát; Guane- stopped at least 14 days before beginning guanethidine, although As for Clonidine Hydrochloride, p.1248. tidino monosulfatas; Monosulfato de guanetidina; NSC-29863 in the USA a minimum of a week has been recommended as ad- Pharmacokinetics (guanethidine hemisulfate); Su-5864 (guanethidine hemisulfate). equate. It has been reported that oral contraceptives may reduce About 75% of an oral dose of guanabenz is absorbed and under- 1-[2-(Perhydroazocin-1-yl)ethyl]guanidine monosulfate. the hypotensive action of guanethidine. Use of digoxin or other goes extensive first-pass metabolism. Peak plasma concentra- digitalis derivatives with guanethidine may cause excessive Гуанетидина Моносульфат bradycardia. tions occur about 2 to 5 hours after a dose. It is about 90% bound C H N ,H SO = 296.4. to plasma proteins. Guanabenz is mainly excreted in urine, al- 10 22 4 2 4 The hypotensive effects of guanethidine may be enhanced by thi- CAS — 55-65-2 (guanethidine); 60-02-6 (guanethidine azide diuretics, other antihypertensives, and levodopa. Alcohol most entirely as metabolites, with less than 1% as unchanged hemisulfate); 645-43-2 (guanethidine monosulfate). may cause orthostatic hypotension in patients taking guanethi- drug; about 10 to 30% is excreted in faeces. The average elimi- ATC — C02CC02; S01EX01. dine. nation half-life is reported to range from 4 to 14 hours. ATC Vet — QC02CC02; QS01EX01. Uses and Administration Pharmacokinetics Guanethidine is variably and incompletely absorbed from the Guanabenz is an alpha2-adrenoceptor agonist with actions and uses similar to those of clonidine (p.1248). It is used in the man- H gastrointestinal tract with less than 50% of the dose reaching the N NH2 systemic circulation. It is actively taken up into adrenergic neu- agement of hypertension (p.1171), either alone or with other N antihypertensives, particularly thiazide diuretics. rones by the mechanism responsible for noradrenaline reuptake. A plasma concentration of 8 nanograms/mL is reported to be Guanabenz is given orally as the acetate, but doses are usually NH necessary for adrenergic blockade, but the dose required to expressed in terms of the base. Guanabenz acetate 5 mg is equiv- achieve this varies between individuals due to differences in ab- alent to about 4 mg of guanabenz. (guanethidine) sorption and metabolism. Guanethidine is partially metabolised In hypertension, the usual dose is 4 mg twice daily initially; the in the liver, and is excreted in the urine as metabolites and daily dose may be increased by amounts of 4 to 8 mg every 1 to Pharmacopoeias. In Eur. (see p.vii), Jpn, and US. unchanged guanethidine. It has a terminal half-life of about 5 2 weeks according to response. Doses of up to 32 mg twice daily Chin. includes the hemisulfate. days. Guanethidine does not penetrate the blood-brain barrier have been used. Ph. Eur. 6.2 (Guanethidine Monosulphate). A colourless crys- significantly. Preparations talline powder. Freely soluble in water; practically insoluble in Uses and Administration USP 31: Guanabenz Acetate Tablets. alcohol. A 2% solution in water has a pH of 4.7 to 5.5. Protect Guanethidine is an antihypertensive that acts by selectively in- from light. Proprietary Preparations (details are given in Part 3) hibiting transmission in postganglionic adrenergic nerves. It is USP 31 (Guanethidine Monosulfate). A white to off-white crys- Braz.: Lisapres; USA: Wytensin. believed to act mainly by preventing the release of noradrenaline talline powder. Very soluble in water; sparingly soluble in alco- at nerve endings. Guanethidine causes the depletion of noradren- hol; practically insoluble in chloroform. A 2% solution in water aline stores in peripheral sympathetic nerve terminals but does has a pH of 4.7 to 5.7. not prevent the secretion of catecholamines by the adrenal me- Guanadrel Sulfate (USAN, rINNM) Adverse Effects dulla. CL-1388R; Guanadrel, Sulfate de; Guanadrel Sulphate; Gua- The commonest adverse effects of guanethidine are severe pos- When given orally its maximal effects may take 1 to 3 weeks to nadreli Sulfas; Sulfato de guanadrel; U-28288D. 1-(Cyclohexane- tural and exertional hypotension and diarrhoea which may be appear on continued dosing and persist for 1 to 3 weeks after spiro-2′-[1′,3′]dioxolan-4′-ylmethyl)guanidine sulfate; 1-(1,4-Di- particularly troublesome during the initial stages of therapy and treatment has been stopped. It causes an initial reduction in car- oxaspiro[4.5]dec-2-ylmethyl)guanidine sulfate. during dose adjustment. Dizziness, syncope, muscle weakness, diac output but its main hypotensive effect is to cause peripheral and lassitude are liable to occur, especially on rising from sitting vasodilatation; it reduces the vasoconstriction which normally Гуанадрела Сульфат or lying. Orthostatic hypotension may be severe enough to pro- results from standing up and which is the result of reflex sympa- (C10H19N3O2)2,H2SO4 = 524.6. voke angina, renal impairment, and transient cerebral ischaemia. thetic nervous activity. In the majority of patients it reduces CAS — 40580-59-4 (guanadrel); 22195-34-2 (guanadrel Other frequent adverse effects are bradycardia, failure of ejacu- standing blood pressure but has a lesser effect on supine blood sulfate). lation, fatigue, headache, and salt and water retention and oede- pressure. When applied topically to the eye guanethidine reduces ma, which may be accompanied by breathlessness and may oc- the production of aqueous humour. casionally precipitate overt heart failure. Guanethidine is used in the management of hypertension NH Nausea, vomiting, dry mouth, nasal congestion, parotid tender- (p.1171). Eye drops of guanethidine have been used for open- ness, blurring of vision, depression, myalgia, muscle tremor, par- angle glaucoma (p.1873) and for lid retraction associated with O aesthesias, hair loss, dermatitis, disturbed micturition, priapism, hyperthyroidism. Guanethidine has also been used in the man- N NH2 H2SO4 aggravation or precipitation of asthma, and exacerbation of pep- agement of neuropathic pain syndromes (see below). H tic ulcer disease have also been reported. Guanethidine may pos- Guanethidine is used in the treatment of hypertension when other O sibly cause anaemia, leucopenia, and thrombocytopenia. 2 drugs have proved inadequate, but it has largely been superseded When guanethidine is used as eye drops, common adverse ef- by other drugs less likely to cause orthostatic hypotension. Tol- fects are conjunctival hyperaemia and miosis. Burning sensa- erance to guanethidine has occurred in some patients; this may Pharmacopoeias. In US. tions and ptosis have also occurred. Superficial punctate keratitis be countered by concomitant diuretic therapy. USP 31 (Guanadrel Sulfate). A white to off-white crystalline has been reported particularly after prolonged use of high
Load more

Recommended publications
  • Table 2. 2012 AGS Beers Criteria for Potentially
    Table 2. 2012 AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults Strength of Organ System/ Recommendat Quality of Recomm Therapeutic Category/Drug(s) Rationale ion Evidence endation References Anticholinergics (excludes TCAs) First-generation antihistamines Highly anticholinergic; Avoid Hydroxyzin Strong Agostini 2001 (as single agent or as part of clearance reduced with e and Boustani 2007 combination products) advanced age, and promethazi Guaiana 2010 Brompheniramine tolerance develops ne: high; Han 2001 Carbinoxamine when used as hypnotic; All others: Rudolph 2008 Chlorpheniramine increased risk of moderate Clemastine confusion, dry mouth, Cyproheptadine constipation, and other Dexbrompheniramine anticholinergic Dexchlorpheniramine effects/toxicity. Diphenhydramine (oral) Doxylamine Use of diphenhydramine in Hydroxyzine special situations such Promethazine as acute treatment of Triprolidine severe allergic reaction may be appropriate. Antiparkinson agents Not recommended for Avoid Moderate Strong Rudolph 2008 Benztropine (oral) prevention of Trihexyphenidyl extrapyramidal symptoms with antipsychotics; more effective agents available for treatment of Parkinson disease. Antispasmodics Highly anticholinergic, Avoid Moderate Strong Lechevallier- Belladonna alkaloids uncertain except in Michel 2005 Clidinium-chlordiazepoxide effectiveness. short-term Rudolph 2008 Dicyclomine palliative Hyoscyamine care to Propantheline decrease Scopolamine oral secretions. Antithrombotics Dipyridamole, oral short-acting* May
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • WO 2013/169741 Al 14 November 2013 (14.11.2013) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2013/169741 Al 14 November 2013 (14.11.2013) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/401 (2006.01) A61P 9/12 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/405 (2006.01) A61P 25/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 31/7048 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US20 13/039904 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 7 May 2013 (07.05.2013) NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (25) Filing Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (26) Publication Language: English ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/644,134 8 May 2012 (08.05.2012) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (72) Inventors; and UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (71) Applicants : STEIN, Emily A.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin Et Al
    US 201201.15729A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0115729 A1 Qin et al. (43) Pub. Date: May 10, 2012 (54) PROCESS FOR FORMING FILMS, FIBERS, Publication Classification AND BEADS FROM CHITNOUS BOMASS (51) Int. Cl (75) Inventors: Ying Qin, Tuscaloosa, AL (US); AOIN 25/00 (2006.01) Robin D. Rogers, Tuscaloosa, AL A6II 47/36 (2006.01) AL(US); (US) Daniel T. Daly, Tuscaloosa, tish 9.8 (2006.01)C (52) U.S. Cl. ............ 504/358:536/20: 514/777; 426/658 (73) Assignee: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF 57 ABSTRACT ALABAMA, Tuscaloosa, AL (US) (57) Disclosed is a process for forming films, fibers, and beads (21) Appl. No.: 13/375,245 comprising a chitinous mass, for example, chitin, chitosan obtained from one or more biomasses. The disclosed process (22) PCT Filed: Jun. 1, 2010 can be used to prepare films, fibers, and beads comprising only polymers, i.e., chitin, obtained from a suitable biomass, (86). PCT No.: PCT/US 10/36904 or the films, fibers, and beads can comprise a mixture of polymers obtained from a suitable biomass and a naturally S3712). (4) (c)(1), Date: Jan. 26, 2012 occurring and/or synthetic polymer. Disclosed herein are the (2), (4) Date: an. AO. films, fibers, and beads obtained from the disclosed process. O O This Abstract is presented solely to aid in searching the sub Related U.S. Application Data ject matter disclosed herein and is not intended to define, (60)60) Provisional applicationpp No. 61/182,833,sy- - - s filed on Jun.
    [Show full text]
  • Antihypertensive Agents Using ALZET Osmotic Pumps
    ALZET® Bibliography References on the Administration of Antihypertensive Agents Using ALZET Osmotic Pumps 1. Atenolol Q7652: W. B. Zhao, et al. Stimulation of beta-adrenoceptors up-regulates cardiac expression of galectin-3 and BIM through the Hippo signalling pathway. British Journal of Pharmacology 2019;176(14):2465-2481 Agents: Isoproterenol; propranolol; carvedilol; atenolol; ICI-118551 Vehicle: saline; ascorbic acid, buffered; Route: SC; Species: Mice; Pump: 2001; Duration: 1 day; 2 days; 7 days; ALZET Comments: Dose ((ISO 0.6, 6, 20 mg/kg/d), (Prop 2 mg/kg/d), (Carv 2 mg/kg/d), (AT 2 mg/kg/d), (ICI 1 mg/kg/d)); saline with 0.4 mM ascorbic acid used; Controls were non-transgenic and received mp w/ vehicle; animal info (12-16 weeks, Male, (C57BL/6J, beta2-TG, Mst1-TG, or dnMst1-TG)); ICI-118551 is a beta2-antagonist with the structure (2R,3S)-1-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]-3-(propan-2-ylamino)butan-2-ol; cardiovascular; Minipumps were removed to allow for washout of ISO overnight prior to imaging; Q7241: M. N. Nguyen, et al. Mechanisms responsible for increased circulating levels of galectin-3 in cardiomyopathy and heart failure. Sci Rep 2018;8(1):8213 Agents: Isoproterenol, Atenolol, ICI-118551 Vehicle: Saline, ascorbic acid; Route: SC; Species: Mice; Pump: Not Stated; Duration: 48 Hours; ALZET Comments: Dose: ISO (2, 6 or 30 mg/kg/day; atenolol (2 mg/kg/day), ICI-118551 (1 mg/kg/day); 0.4 mM ascorbic used; animal info (12 14 week-old C57Bl/6 mice); cardiovascular; Q6161: C.
    [Show full text]
  • Association of Oral Anticoagulants and Proton Pump Inhibitor Cotherapy with Hospitalization for Upper Gastrointestinal Tract Bleeding
    Supplementary Online Content Ray WA, Chung CP, Murray KT, et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA. doi:10.1001/jama.2018.17242 eAppendix. PPI Co-therapy and Anticoagulant-Related UGI Bleeds This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Appendix: PPI Co-therapy and Anticoagulant-Related UGI Bleeds Table 1A Exclusions: end-stage renal disease Diagnosis or procedure code for dialysis or end-stage renal disease outside of the hospital 28521 – anemia in ckd 5855 – Stage V , ckd 5856 – end stage renal disease V451 – Renal dialysis status V560 – Extracorporeal dialysis V561 – fitting & adjustment of extracorporeal dialysis catheter 99673 – complications due to renal dialysis CPT-4 Procedure Codes 36825 arteriovenous fistula autogenous gr 36830 creation of arteriovenous fistula; 36831 thrombectomy, arteriovenous fistula without revision, autogenous or 36832 revision of an arteriovenous fistula, with or without thrombectomy, 36833 revision, arteriovenous fistula; with thrombectomy, autogenous or nonaut 36834 plastic repair of arteriovenous aneurysm (separate procedure) 36835 insertion of thomas shunt 36838 distal revascularization & interval ligation, upper extremity 36840 insertion mandril 36845 anastomosis mandril 36860 cannula declotting; 36861 cannula declotting; 36870 thrombectomy, percutaneous, arteriovenous
    [Show full text]
  • DOCUMENT RESUME ED 303 441 SP 030 865 TITLE Detection
    DOCUMENT RESUME ED 303 441 SP 030 865 TITLE Detection, Evaluation, and Treatment of High Blood Pressure. Report of the Committee. INSTITUTION National Heart, Lung, and Blood Inst. (DHHS/NIH), Bethesda, MD. PUB DATE 88 NOTE 64p. PUB TYPE Guides - Non-Classroom Use (055) EDRS PRICE MF01/PC03 Plus Postage. DESCRIPTORS *Cardiovascular System; Clinical Diagnosis; *Drug Therapy; *Hypertension; *Pharmacology; Physical Examinations; Physical Health; *Physical Therapy ABSTRACT The availability of an increased variety of therapeutic approaches provides the opportunitl to improve hypertension control while minimizing adverse effects that may influence cardiovascular complications and adherence to therapy. This report serves two purposes: (1) to guide practicing physicians and other health professionals in their care of hypertensive patients; and (2) to guide health professionals participating in the many community high blood pressure control programs. Contents include: (1) definition and prevalence of high blood pressure; (2) detection, confirmation and referral; (3) evaluation and diagnosis; (4) treatment--nonpharmacologic and pharmacologic therapy, and long-term maintenance of therapy; (5) considerations in individual therapy; and (6) special populations and management problems. Fifty-five references are included. (JD) *********************************************************************** Reproductions supplied by EDRS are the best that can be made from the original document. ************************************-*********************************
    [Show full text]
  • And Antagonists Between the Pithed Rabbit and Rat J.M
    Br. J. Pharmac. (1987), 91, 457-466 Difference in the potency ofa2-adrenoceptor agonists and antagonists between the pithed rabbit and rat J.M. Bulloch, 'J.R. Docherty, 2N.A. Flavahan, J.C. McGrath & C.E. McKean Institute ofPhysiology, University ofGlasgow, Glasgow G12 8QQ, Scotland 1 The subtypes ofa-adrenoceptors which mediate pressor responses to sympathomimetic agonists or to nerve stimulation in pithed rabbits have been classified according to the effects of 'selective' antagonists and a comparison has been made, for the xt2-subtype, with corresponding responses in the rat. 2 In the rabbit the dose-response curve for phenylephrine was shifted to the right in parallel by prazosin (1 mg kg-') and was unaffected by rauwolscine (1 mg kg '). The dose-response curve for noradrenaline was shifted to the right by prazosin (I mg kg -') and was shifted to a smaller extent by rauwolscine (1 mg kg -') or imiloxan (1Omg kg-'). After rauwolscine, prazosin produced a rightward shift larger than when given alone. After prazosin, rauwolscine produced a rightward shift larger than when given alone. 3 The responses to pressor nerve stimulation at low frequencies (< 1 Hz) could be reduced by prazosin, rauwolscine or imiloxan but those at a higher frequency could be reduced only by prazosin. 4 These results indicate that the responses to noradrenaline or to nerve stimulation are mediated by both a,- and a2-adrenoceptors. Low doses or frequencies have a proportionately greater component which is M2 5 Responses to noradrenaline after prazosin (1 mg kg -'), were sufficiently sensitive to rauwolscine to be considered as predominantly a2.
    [Show full text]
  • Current and Experimental Therapeutics for the Treatment of Opioid Addiction
    105 CURRENT AND EXPERIMENTAL THERAPEUTICS FOR THE TREATMENT OF OPIOID ADDICTION PAUL J. FUDALA GEORGE E. WOODY Currently, numerous effective pharmacologic and behav- ing treatment have been addicted to heroin or other opioids ioral therapies are available for the treatment of opioid ad- for 2 to 3 years, some for 30 years or more. Thus, treatment diction, and these two types of therapies often are combined usually involves changes in patients’ lifestyles. Although to optimize patient management. Newer therapeutic op- generally ineffective in producing sustained remission unless tions may take various forms. For example, methadone combined with long-term pharmacologic, psychosocial, or maintenance is an established treatment modality, whereas behavioral therapies, detoxification alone continues to be the use of buprenorphine and naloxone in an office-based widely used and studied. It is sometimes the only option setting represents a new variation on that theme. Clonidine available for patients who do not meet United States Food has been used extensively to ameliorate opioid withdrawal and Drug Administration (FDA) criteria for, do not desire, signs, whereas lofexidine is a structural analogue that ap- or do not have access to agonist medications such as metha- pears to have less hypotensive and sedating effects. The done or methadyl acetate (L-␣-acetylmethadol or LAAM). depot dosage form of naltrexone, currently under develop- The detoxification process may include use of opioid ment, may increase compliance with a medication that has agonists (e.g., methadone), partial agonists (e.g., buprenor- been an effective opioid antagonist but that has been un- phine), antagonists (e.g., naloxone, naltrexone), or nonopi- derused secondary to patient nonacceptance.
    [Show full text]
  • Add-On Effect of Bedtime Dosing of the Α1-Adrenergic Receptor
    1097 Hypertens Res Vol.30 (2007) No.11 p.1097-1105 Original Article Add-On Effect of Bedtime Dosing of the α1 -Adrenergic Receptor Antagonist Doxazosin on Morning Hypertension and Left Ventricular Hypertrophy in Patients Undergoing Long-Term Amlodipine Monotherapy Toshio IKEDA1), Tomoko GOMI1), Yuko SHIBUYA1), Shingo SHINOZAKI1), Yoshifumi SUZUKI1), and Nami MATSUDA1) High morning blood pressure is related to target organ damage and future cardiovascular events. Chrono- biologic therapies focusing on the early morning period may be an important strategy for antihypertensive therapy. The aim of this study was to clarify the add-on effects of bedtime dosing of the α1 -adrenergic recep- tor antagonist doxazosin on morning blood pressure in patients with essential hypertension who were under long-acting calcium channel blocker amlodipine monotherapy. The add-on effects of doxazosin at the max- imum dose of 6 mg at bedtime on home blood pressure and left ventricular geometry for 1 year were inves- tigated in 49 subjects (37 men and 12 women, aged 57.5±9.1 years) with morning hypertension who had been treated with amlodipine alone for more than 1 year. Doxazosin induced a significant decrease in morn- ing blood pressure (145.6±5.6/91.5±5.4 to 132.4±3.7/83.6±5.6 mmHg, p≤0.001/<0.001) without a change of evening blood pressure (128.9±5.1/79.8±5.1 to 127.7±6.0/78.8±6.2 mmHg, p=0.056/0.051). Left ventricular mass index (LVMI; 124.8±19.8 to 95.6±15.7 g/m2, p<0.001), relative wall thickness (0.457±0.061 to 0.405±0.047, p<0.001) and homeostasis model assessment of the insulin resistance index (HOMA-IR; 2.62±1.43 to 1.33±0.75, p<0.001) were decreased after doxazosin therapy.
    [Show full text]
  • Initial Medication Selection for Treatment of Hypertension in an Open-Panel HMO
    J Am Board Fam Pract: first published as 10.3122/jabfm.8.1.1 on 1 January 1995. Downloaded from Initial Medication Selection For Treatment Of Hypertension In An Open-Panel HMO Micky jerome, PharmD, MBA, George C. Xakellis, MD, Greg Angstman, MD, and Wayne Patchin, MBA Background: During the past 25 years recommendations for treating hypertension have evolved from a stepped-care approach to monotherapy or sequential monotherapy as experience has been gained and new antihypertensive agents have been introduced. In an effort to develop a disease management strategy for hypertension, we investigated the prescribing patterns of initial medication therapy for newly treated hypertensive patients. Methods: We examined paid claims data of an open-panel HMO located in the midwest. Charts from 377 patients with newly treated hypertension from a group of 12,242 hypertenSive patients in a health insurance population of 85,066 persons were studied. The type of medication regimen received by patients newly treated for hypertension during an 18-month period was categorized into monotherapy, sequential monotherapy, stepped care, and initial treatment with multiple agents. With monotherapy, the class of medication was also reported. Associations between use of angiotensin-converting enzyme (ACE) inhibitors, calcium channel blockers, or (3-blockers and presence of comorbid conditions were reported. Results: Fifty-five percent of patients received monotherapy, 22 percent received stepped care, and 18 percent received sequential monotherapy. Of those 208 patients receiving monotherapy, 30 percent were prescribed a calcium channel blocker, 22 percent an ACE inhibitor, and 14 percent a f3-blocker. No customization of treatment for comorbid conditions was noted.
    [Show full text]